trimethylamine has been researched along with Fatty Liver, Nonalcoholic in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 8.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder with complicated pathophysiology." | 5.72 | Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. ( Abdi, M; Ghaderi, D; Moloudi, MR; Moradzad, M; Rahmani, K; Sheikh Esmaeili, F; Vahabzadeh, Z, 2022) |
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 4.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "The spectrum of NAFLD includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, liver cirrhosis, and even hepatocellular carcinoma." | 2.61 | Microbial metabolites in non-alcoholic fatty liver disease. ( Fan, JG; Zhou, D, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder with complicated pathophysiology." | 1.72 | Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. ( Abdi, M; Ghaderi, D; Moloudi, MR; Moradzad, M; Rahmani, K; Sheikh Esmaeili, F; Vahabzadeh, Z, 2022) |
| "Liver fibrosis is one main histological characteristic of nonalcoholic steatohepatitis (NASH), a disease paralleling a worldwide surge in metabolic syndromes with no approved therapies." | 1.72 | Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. ( Ding, BS; Mo, C; Xiao, C; Zhang, J; Zhou, D, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, C | 1 |
| Pei, M | 1 |
| Wang, Y | 1 |
| Chen, Q | 1 |
| Cao, P | 1 |
| Zhang, L | 1 |
| Guo, J | 1 |
| Deng, W | 1 |
| Wang, L | 1 |
| Li, X | 1 |
| Gong, Z | 1 |
| Moradzad, M | 1 |
| Abdi, M | 1 |
| Sheikh Esmaeili, F | 1 |
| Ghaderi, D | 1 |
| Rahmani, K | 1 |
| Moloudi, MR | 1 |
| Vahabzadeh, Z | 1 |
| Zhou, D | 2 |
| Zhang, J | 1 |
| Xiao, C | 1 |
| Mo, C | 1 |
| Ding, BS | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| Flores-Guerrero, JL | 1 |
| Post, A | 1 |
| van Dijk, PR | 1 |
| Connelly, MA | 1 |
| Garcia, E | 1 |
| Navis, G | 1 |
| Bakker, SJL | 1 |
| Dullaart, RPF | 1 |
| Chu, H | 1 |
| Duan, Y | 1 |
| Yang, L | 1 |
| Schnabl, B | 1 |
| Fan, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Alterations of Gut Microbiota and Metabolites in Asian Patients With Alcohol-associated Liver Disease[NCT05448144] | 200 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for trimethylamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
Topics: Bile Acids and Salts; Disease Progression; Dysbiosis; Ethanol; Fatty Acids, Volatile; Gastrointestin | 2019 |
Microbial metabolites in non-alcoholic fatty liver disease.
Topics: Bile Acids and Salts; Disease Progression; Ethanol; Fatty Acids, Volatile; Fermentation; Gastrointes | 2019 |
4 other studies available for trimethylamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine.
Topics: Animals; Cell Line; Endoplasmic Reticulum Chaperone BiP; Gastrointestinal Microbiome; Gene Silencing | 2022 |
Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease.
Topics: Case-Control Studies; Chromatography, Liquid; Flavins; Humans; Methylamines; Mixed Function Oxygenas | 2022 |
Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis.
Topics: Animals; Disease Models, Animal; Gastrointestinal Microbiome; Liver Cirrhosis; Methylamines; Mice; N | 2022 |
Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease.
Topics: Biomarkers; Cohort Studies; Humans; Methylamines; Non-alcoholic Fatty Liver Disease; Oxides; Prospec | 2021 |